Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
Key Highlights
- ➤Six Veracyte genomic-test studies will be presented at ESMO Congress 2026
- ➤Decipher Prostate may predict abiraterone benefit in very high-risk nonmetastatic disease
- ➤OPTIMA analysis evaluates chemotherapy decisions guided by Prosigna’s 50-gene assay
- ➤Studies span treatment selection and risk assessment across prostate and bladder cancers
Expert Statements
Phillip Febbo, Chief scientific and medical officer of Veracyte
“The research being presented at ESMO reflects how understanding a tumor’s biology can inform decisions across cancer care.”
Phillip Febbo, Chief scientific and medical officer of Veracyte
“The Decipher Prostate study will provide the first evidence that the test predicts benefit from adding abiraterone to treatment for patients with clinically very high-risk disease.”
Phillip Febbo, Chief scientific and medical officer of Veracyte
“Alongside the OPTIMA economic analysis and new bladder cancer research, these studies address questions that matter to patients and clinicians.”
Oral presentations include new Decipher treatment-selection evidence and an OPTIMA breast cancer health economic analysis
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that six studies involving its genomic tests will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The presentations span treatment selection and risk assessment in prostate and bladder cancer, as well as a late-breaking health economic analysis from the Phase III landmark OPTIMA breast cancer trial.
Get started
Create a free account to read the full story.